title: Exploratory analysis of estimated acoustic peak rarefaction pressure, recanalization, and outcome in the transcranial ultrasound in clinical sonothrombolysis trial.
abstract: OBJECTIVE
  Acoustic peak rarefaction pressure (APRP) is the main factor that influences ultrasound-enhanced thrombolysis. We sought to determine whether recanalization rate and functional outcomes in the Transcranial Ultrasound in Clinical SONothrombolysis (TUCSON) trial could be predicted by estimated in vivo APRP.
  
  
  METHODS
  We developed an acoustic attenuation model to estimate the in vivo APRP at the arterial occlusion site in each subject of the TUCSON trial with CT scans eligible for measurements. Variables included temporal bone thickness, depth of arterial occlusion site, and average attenuation of skin and brain tissues. Recanalization was defined as partial or complete using the Thrombolysis in Brain Infarction flow grades. Functional independence was assessed at 3 months using the modified Rankin Scale score (mRS, 0-1).
  
  
  RESULTS
  APRP was calculated in 20 acute ischemic stroke patients treated with sonothrombolysis (mean age, 64 ± 15 years, 65% men; median NIHSS score, 13; IQR, 6-17). The mean APRP was 30.2 ± 15.5 kPa (range, 8-68 kPa). Patients with persisting occlusion had nonsignificantly lower APRP than patients with partial or complete recanalization (25.2 ± 8.0 versus 32.3 ± 17.7 kPa; p = 0.228). Patients who were functionally independent at 3 months had nonsignificantly higher APRP than patients with worse outcome (35.1 ± 19.5 versus 25.9 ± 11.2 kPa; p = 0.217).
  
  
  CONCLUSIONS
  Our exploratory analysis suggests a potentially important role of successful energy delivery to augment thrombolysis with 2-MHz ultrasound in acute ischemic stroke patients.
authors.affiliation: Comprehensive Stroke Center, University of Alabama Hospital, Birmingham, AL, USA.
authors.forename: Kristian
authors.initials: K
authors.lastname: Barlinn
authors.forename: Georgios
authors.initials: G
authors.lastname: Tsivgoulis
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Molina
authors.forename: Dmitri A
authors.initials: DA
authors.lastname: Alexandrov
authors.forename: Mark E
authors.initials: ME
authors.lastname: Schafer
authors.forename: John
authors.initials: J
authors.lastname: Alleman
authors.forename: Andrei V
authors.initials: AV
authors.lastname: Alexandrov
mesh_terms: D000368:Aged; D001696:Biomechanical Phenomena; D002544:Cerebral Infarction / Q000000981:diagnostic imaging* / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D016015:Logistic Models; D008297:Male; D061185:Mechanical Thrombolysis / Q000379:methods*; D008863:Microspheres; D008875:Middle Aged; D008954:Models, Biological; D011312:Pressure; D020127:Recovery of Function; D012189:Retrospective Studies; D016037:Single-Blind Method; D015912:Thrombolytic Therapy / Q000379:methods; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D017585:Ultrasonography, Doppler, Transcranial; D018084:Ultrasonography, Interventional
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator